Intra-Cellular Therapies (ITCI): Previewing Phase III 302 of ITI-007 In Schizophrenia - Piper Jaffray

September 13, 2016 6:47 AM EDT
Get Alerts ITCI Hot Sheet
Price: $14.93 +1.01%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ITCI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Charles Duncan, previewed results from on Intra-Cellular Therapies' (NASDAQ: ITCI) second Phase III “302” trial of ITI-007 in schizophrenia. The analyst expects the results during 2H16 and potentially as soon as early October.

The analyst is optimistic that ‘007 60mg represents an active dose and can generate stat sig improvement over placebo against the primary endpoint of total PANSS. The analyst also expects placebo-like tolerability versus Risperdal across the 6 week study can support a meaningfully differentiated clinical profile for ‘007.

No change to the Overweight rating or price target of $57.

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $43.78 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Piper Jaffray, The Children's Investment Fund (TCI), Charles Duncan

Add Your Comment